You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》里昂下调上海医药(02607.HK)目标价至19.32元 评级「买入」
阿思达克 03-31 10:20
里昂发表报告指,上海医药(02607.HK)去年纯利按年增长10.5%至45亿元人民币,符合市场预期,收入则按年上升2.9%至1,919亿元。

该行表示,集团去年下半年表现显示其於疫情中强劲复苏,收入及盈利按年分别增长11.4%及14.4%。而管理层指引在今年底,创新药产品线会扩至35款候选药物,当中六款已进入三期临床。

里昂下调上海医药股份目标价,由24.04元降至19.32元,评级维持「买入」,并预期集团今年至2023年收入可分别增长18.5%、17.2%及16.7%,纯利则按年上升18.1%、11.1%及18.1%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account